Objective: To investigate the expression and the possible mechanism of the transcription factor C/EBPα in chronic myeloid leukemia(CML).
Methods: Bone marrow samples from 50 CML patients(including 33 patients in chronic phase, 7 in accelerated phase and 10 in blast crisis)and peripheral blood specimens of 20 healthy donors were collected. The expression of C/EBPα gene and the effect of Imatinib on its expression was detected by RT- PCR. C/EBPα gene was inserted into lentivirus expression vector pLVX- EGFP- 3FLAG- Puro by recombinant DNA technology to construct C/EBPα stable expression in K562 cells. Cell proliferation was assayed by CCK-8. The expressions of Foxo3a and Bim genes were detected by RT-PCR.
Results: The level of C/EBPα expression was significantly declined in CML patients compared with that of normal control group(P<0.01)and had negative correlation with bcr- abl expression(Spearman r=- 0.505, P<0.01). The stable K562- C/EBPα cell line was successfully established and confirmed by RT-PCR and Western blot. Cell proliferation ability was lower in the K562- C/EBPα group than that in the non- transfection and mock-vehicle groups. The expressions of Foxo3a and Bim genes were 1.06 ± 0.06 and 0.53 ± 0.07, respectively, which was higher than that of nontransfection and mock-vehicle groups(P<0.01, P<0.05).
Conclusion: C/EBPα expression was decreased in CML patients, overexpression of C/EBPα could inhibit K562 cell growth.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342430 | PMC |
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.11.012 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!